Results 111 to 120 of about 3,564 (173)

Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry. [PDF]

ERJ Open Res
Stahl M, Gerts FS, Hafkemeyer S, Wosniok J, Naehrlich L, German CF Registry of the Mukoviszidose e.V. and participating sites.   +5 more
europepmc   +1 more source

12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]

Genet Med Open
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc   +1 more source

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial [PDF]

BACKGROUND: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor–tezacaftor–deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator ...
Tullis, E, Pittman, JE, Rodriguez-Romero, V, Thia, LP, Ramsey, B, Zhu, J, Tirakitsoontorn, P, Sosnay, PR, Hoppe, JE, Robinson, P, Mall, MA, McKone, EF, Salinas, DB, Taylor-Cousar, JL, Davies, G, Kasi, AS, Jensen, R, Chen, YC   +17 more
core  

Predictive capacity of paediatric nasal epithelial cells in sequential CFTR modulator therapy. [PDF]

Thorax
Fawcett LK, Chew ZA, Schneider-Futschik EK, Allan KM, Patel HR, Jaffe A, Waters S.   +6 more
europepmc   +1 more source

Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]

J Clin Med
Boni A, Vassallo C, Ciciriello F, Cristiani L, Mancini A, Zucaro L, Graziano S, Goffredo BM, Alghisi F, Raponi M, Fabietti I, On Behalf Of Opbg Cf Pregnancy And Fetal Therapy Multidisciplinary Group.   +11 more
europepmc   +1 more source

Effect of Elexacaftor/Tezacaftor/Ivacaftor Treatment on Extrapulmonary Complications of Cystic Fibrosis. [PDF]

Adv Ther
Geiger JM, Brady BL, Lew CR, Jennings M, Mo C, Van Brunt K, Dezube R.   +6 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Sinonasal and Pulmonary Computed Tomography Images Before and After Triple-Combination Therapy in a Patient with Cystic Fibrosis Without ΔF508 Mutations. [PDF]

Diagnostics (Basel)
Tagliati C, Campagna G, Di Sabatino M, Lanni G, Battista D, Ripani P.   +5 more
europepmc   +1 more source

Long-term impact of elexacaftor/tezacaftor/ivacaftor on small and large airways in people with cystic fibrosis aged ≥6 years: 24-month real-world evidence from the German Cystic Fibrosis Registry. [PDF]

ERJ Open Res
Dillenhöfer S, Schütz K, Burkhart M, Ellemunter H, Kappler M, Sieber S, Naehrlich L, Brinkmann F, Sutharsan S.   +8 more
europepmc   +1 more source

Elexacaftor, Tezacaftor, and Ivacaftor

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source